Monte Rosa Therapeutics announced that the first participants have been dosed in a Phase 1, single ascending dose / multiple ascending dose, healthy volunteer study evaluating MRT-6160, a VAV1-directed MGD being developed for systemic and neurological autoimmune diseases. The Company expects to obtain initial data from the Phase 1 study in Q1 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics price target lowered to $17 from $18 at Wells Fargo
- Monte Rosa Therapeutics sees cash runway into 1H27
- Monte Rosa Therapeutics achieves milestones under Roche collaboration agreement
- Monte Rosa Therapeutics announces FDA acceptance of IND for MRT-6160
- Monte Rosa Therapeutics reports Q2 EPS (43c), consensus (54c)
Questions or Comments about the article? Write to editor@tipranks.com